Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCreative Medical Technology Holdings Inc

Creative Medical Technology Holdings Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.631 USD 0.01 ( 1.45%)
Last update at 2026-11-09T15:36:00Z
VOLUME
26574
Market Cap
8.35M

Momentum Score

…

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.61
Low
0.64
High
52 Week Price Range
1.50
Low
6.25
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Creative Medical Technology Holdings, Inc. is a small-cap company focused on developing and commercializing regenerative medicine and cell-based therapies, with public activities concentrated on clinical-stage products and related services. Long-term growth may be supported by successful clinical milestones, wider adoption of biologic treatments, and broader market penetration of cell-based interventions, and investors may find exposure to potential upside from product commercialization and participation in an expanding regenerative medicine sector.
Material risks include regulatory uncertainty, limited scale and liquidity, ongoing operating losses with likely dilution, competitive pressure and uncertain reimbursement environments.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.62
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
0.00
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-86.47%
Net Debt
-7.21M
ROCE
-81.64%
Diluted EPS TTM
-2.52

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.00M -5.49M -5.29M -10.14M 19.21M
Net income -6.00M -5.49M -5.29M -10.04M 14.93M
Selling general administrative 3.76M 3.24M 3.06M 3.94M 2.96M
Gross profit -0.12M 0.01M 0.01M 0.06M 0.04M
Reconciled depreciation 0.12M 0.11M 0.09M 0.09M 0.09M
Ebit -6.14M -5.74M -5.62M -10.24M -3.13M
Ebitda -6.02M -5.63M -5.53M -10.05M -3.03M
Depreciation and amortization 0.12M 0.11M 0.09M 0.19M 0.09M
Operating income -6.14M -5.74M -5.62M -10.24M -3.13M
Other operating expenses 6.15M 5.75M 5.63M 10.33M 3.21M
Interest expense - - - -0.10M 4.28M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.15M 0.25M 0.30M 0.10M -
Net interest income 0.15M 0.25M 0.30M 0.10M -4.28M
Income tax expense - - -0.00M -0.10M 4.28M
Total revenue 0.01M 0.01M 0.01M 0.09M 0.09M
Total operating expenses 6.02M 5.75M 5.63M 10.30M 3.17M
Cost of revenue 0.13M 0.00M 0.00M 0.03M 0.05M
Total other income expense net 0.15M 0.25M 0.33M 0.10M 22.34M
Net income from continuing ops -6.00M -5.49M -9.82M -10.14M 19.21M
Net income applicable to common shares - - - - 19.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.81M 6.67M 10.72M 19.19M 11.27M
Intangible assets 0.41M 0.53M 0.44M 0.44M 0.53M
Other current assets 0.14M 0.19M 0.28M 10.42M -
Total liab 0.28M 0.33M 0.37M 3.32M 1.05M
Total stockholder equity 7.51M 6.34M 10.34M 15.86M 10.22M
Other current liab 0.01M 0.05M 0.05M 0.05M 0.29M
Common stock 0.00M 0.00M 0.00M 0.01M 0.01M
Capital stock 0.00M 0.00M 0.00M 0.01M 0.01M
Retained earnings -70.59M -64.59M -59.10M -53.81M -43.67M
Other assets - - 0.00M - 0.00M
Cash 7.21M 5.94M 3.47M 18.40M 10.72M
Total current liabilities 0.28M 0.33M 0.37M 3.32M 1.05M
Current deferred revenue - - -0.01M - -
Net debt -7.21M -5.94M -3.45M -18.40M -10.72M
Short term debt - 0.01M 0.01M - -
Short long term debt total - 0.01M 0.01M - -
Other stockholder equity 78.10M 70.93M 69.44M 69.66M 53.88M
Total current assets 7.40M 6.14M 10.27M 18.75M 10.74M
Net tangible assets - - - 15.43M 9.69M
Short term investments - 0.00M 6.52M 10.08M -
Net receivables 0.05M - - -10.08M 0.00M
Inventory 0.00M 0.00M 0.01M 0.01M 0.01M
Accounts payable 0.27M 0.27M 0.32M 3.27M 0.76M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 0.00M 0.00M 0.00M 0.00M 0.00M
Non current assets total 0.41M 0.53M 0.44M 0.44M 0.53M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 6.32M -2.74M -10.08M 0.00M
Change to liabilities - - - 2.51M 0.41M
Total cashflows from investing activities -0.05M 6.32M 3.45M - -
Net borrowings - - - - -1.63M
Total cash from financing activities 7.17M 1.45M -0.27M 15.47M 12.84M
Change to operating activities - - - - -0.15M
Net income -6.00M -5.49M -5.29M -10.14M 19.21M
Change in cash 1.27M 2.47M -4.85M -2.40M 10.63M
Begin period cash flow 5.94M 3.47M 8.32M 10.72M 0.10M
End period cash flow 7.21M 5.94M 3.47M 8.32M 10.72M
Total cash from operating activities -5.86M -5.30M -8.03M -7.80M -2.22M
Issuance of capital stock 7.17M 1.63M 0.00M 15.47M 15.22M
Depreciation 0.12M 0.11M 0.09M 0.09M 0.09M
Other cashflows from investing activities -0.05M 6.32M -0.10M - -
Dividends paid - - - - -4.78M
Change to inventory 0.00M 0.00M 0.00M 0.00M -0.01M
Change to account receivables - - 0.00M 0.00M -0.00M
Sale purchase of stock -0.01M -0.17M -0.27M 0.00M -0.20M
Other cashflows from financing activities 0.01M 0.00M 3.45M 0.00M 9.02M
Change to netincome - - - - -25.93M
Capital expenditures 0.00M 0.20M 0.10M 0.00M 0.00M
Change in working capital 0.01M 0.05M -2.84M 2.19M 0.25M
Stock based compensation 0.00M 0.04M 0.04M 0.07M 0.60M
Other non cash items 0.01M 0.05M -0.03M - 4.16M
Free cash flow -5.86M -5.30M -8.13M -7.80M -2.22M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CELZ
Creative Medical Technology Holdings Inc		 0.01
1.45%		 0.63 - - 1392.41 1.11 191.06 -1.45
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Creative Medical Technology Holdings Inc

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

211 East Osborn Road, Phoenix, AZ, United States, 85012

480 399 2822

https://www.creativemedicaltechnology.com

4

Name Title Year Born
Mr. Timothy Warbington Chairman, Pres & CEO 1962
Mr. Donald Dickerson Sr. VP, CFO & Director 1965
Mr. Timothy Warbington Co-Founder, Chairman, President & CEO 1962
Mr. Donald Dickerson Senior VP, CFO & Director 1965
Mr. Donald F. Dickerson MBA Senior VP, CFO & Director 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…